46 completed, 10 unknown, 9 terminated, 8 recruiting. 36 Phase 3, 19 Phase 2, 11 Phase 4, 4 Phase 1, 2 Not applicable.
Follow benralizumab: new trials by email Literature Review of benralizumab trials Research Report on benralizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome | Phase 2 | Not yet recruiting | University Hospital, Lille | 96 | 2027-01-06 | 2026-05-15 |
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-09-22 |
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| Benralizumab Effectiveness in EGPA Benralizumab 30 mg/ml - Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Recruiting | European EGPA Study Group | 100 | 2026-02-11 | 2026-09-11 | |
| A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy benralizumab - Severe Eosinophilic Asthma | Recruiting | AstraZeneca | 335 | 2025-12-20 | 2026-09-18 | |
| Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis Fasenra - Allergic Bronchopulmonary Aspergillosis, Severe Asthma | Recruiting | Qianfoshan Hospital | 20 | 2025-09-01 | 2026-04-21 | |
| This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab benralizumab - Chronic Obstructive Pulmonary Disease | Recruiting | AstraZeneca | 1000 | 2025-07-11 | 2026-07-22 | |
| A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases Benralizumab - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES) | Phase 3 | Recruiting | AstraZeneca | 14 | 2025-04-17 | 2026-09-18 |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment ICS-LABA, benralizumab, Placebo for Benralizumab - Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 130 | 2025-03-28 | 2026-10-16 |
| BenRalizumab Effect on Airway Remodeling in Severe asTHma Benralizumab 30 mg/ml - Asthma; Eosinophilic, Airway Remodeling | Phase 4 | Unknown | Aristotle University Of Thessaloniki | 45 | 2024-03-01 | 2024-03-04 |
| STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma Benralizumab - Severe Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 504 | 2024-02-28 | 2026-09-03 |
| Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping Dupilumab, Benralizumab - Moderate to Severe Asthma | Phase 4 | Recruiting | University of California, San Diego | 120 | 2024-02-19 | 2024-08-19 |
| Fluctuation Analyses of Asthma Patients With Biologics Use Biological Drug - Asthma | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 48 | 2023-12-01 | 2023-11-01 | |
| Taiwan Severe Asthma Biologic Registry Biological Treatment for severe asthma patients - Pulmonary Disease, Asthma | Recruiting | Taichung Veterans General Hospital | 500 | 2023-11-11 | 2026-05-19 | |
| Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC) Fasenra Prefilled Syringe, Matching Placebo Solution - Chronic Prurigo | Phase 2 | Withdrawn | Charite University, Berlin, Germany | 2023-10-01 | 2024-01-08 | |
| A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer Benralizumab, fulvestrant or AIs) and PI3K inhibition (alpelisib) - Breast Cancer | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 1 | 2023-07-06 | 2024-08-29 |
| Response and Remission to Treatment With Anti-IL5/IL5R Antagonists Mepolizumab - Asthma | Completed | Université de Montréal | 109 | 2023-06-01 | 2024-04-04 | |
| Beyond the Eosinophil: Understanding the Impact of Eosinophil Depletion on T2 Inflammation. (BEUTI) Benralizumab - Asthma | Unknown | Guy's and St Thomas' NHS Foundation Trust | 12 | 2023-05-22 | 2023-07-11 | |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma Benralizumab, Placebo - Asthma | Phase 3 | Active not recruiting | AstraZeneca | 94 | 2023-04-05 | 2026-09-29 |
| Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD) Benralizumab, Benralizumab placebo, Comparison (control) group; no intervention - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Unknown | Temple University | 45 | 2023-04-01 | 2023-04-07 |
Showing 20 of 83. Sign in to see all of them.
Asthma (48) · Lung Diseases (15) · Pulmonary Eosinophilia (13) · Respiratory Tract Diseases (13) · Bronchial Diseases (12) · Lung Diseases, Obstructive (12) · Pulmonary Disease, Chronic Obstructive (6) · Nasal Polyps (5) · Churg-Strauss Syndrome (4) · Eosinophilia (3) · Pruritus (3) · Aspergillosis, Allergic Bronchopulmonary (2) · Chronic Urticaria (2) · Dermatitis, Atopic (2) · Eosinophilic Esophagitis (2)
AstraZeneca (42) · MedImmune LLC (6) · McMaster University (2) · Memorial Sloan Kettering Cancer Center (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Aristotle University Of Thessaloniki (1) · Baylor Research Institute (1) · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal (1) · Charite University, Berlin, Germany (1) · Children's Hospital Medical Center, Cincinnati (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Dr. Grace Parraga (1) · Endeavor Health (1) · European EGPA Study Group (1) · GlaxoSmithKline (1)
United States (49) · Canada (29) · Germany (25) · France (22) · Poland (22) · Spain (22) · United Kingdom (22) · Italy (20) · Japan (14) · Argentina (13) · Bulgaria (12) · South Korea (12) · Australia (10) · China (10) · Belgium (9)
Alina Markova, MD (2) · Catherine Lemiere, MD (2) · Gary T. Ferguson, MD, PC (2) · Marc E. Rothenberg, MD, PhD (2) · Michael Wechsler, MD (2) · Amy D Klion, M.D. (1) · Brad Goodman, MD (1) · Claus Bachert, Prof. dr. h.c. (1) · David Gossage, M.D. (1) · David Gossage, M.D., MBA (1) · David J Jackson, MRCP MSc PhD (1) · Donald Raible, MD (1) · Dr. David Jackson (1) · Dr. Pablo Forte-Soto (1) · Dr. Rainard Fuhr, Medicine (1)
PMID 30802500, PMID 33710614, PMID 35287231, PMID 25445859, PMID 27609406, PMID 27609408, PMID 29409951, PMID 30077185, PMID 30139780, PMID 30658649, PMID 31579676, PMID 31626906, PMID 31836949, PMID 32334141, PMID 33369570, PMID 34110505, PMID 38393328, PMID 12045120, PMID 21037369, PMID 25208464, PMID 25306557, PMID 28461289, PMID 28514601, PMID 29128192, PMID 29221581, PMID 30416083, PMID 31310686, PMID 31391226, PMID 31539289, PMID 31719529, PMID 31798645, PMID 32453217, PMID 32762056, PMID 33001543, PMID 33027187, PMID 33065367, PMID 33164993, PMID 33357499, PMID 33595845, PMID 33609624, PMID 33718405, PMID 34347947, PMID 34599979, PMID 34619104, PMID 35283104, PMID 35283330, PMID 35850947, PMID 35896216, PMID 36781102, PMID 36927642
2019 (5), 2023 (5), 2017 (3), 2018 (3), 2014 (1), 2016 (1), R01HL161362 (1)